Kane Biotech Inc. (KNE.V)
| Previous Close | 0.0850 |
| Open | 0.0900 |
| Bid | 0.0750 x 0 |
| Ask | 0.0850 x 0 |
| Day's Range | 0.0800 - 0.0900 |
| 52 Week Range | 0.0500 - 0.1500 |
| Volume | |
| Avg. Volume | 35,507 |
| Market Cap | 10.548M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Nov 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireKane Biotech Announces Improved Third Quarter 2023 Financial Results
29% Increase in Product and Services Revenue; 26% Increase in Total RevenueWINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights: Revenue from product and services for the three months ended September 30, 2023 was $548,785 an increase of 29% from $425,671 in the three months ended September 30, 2022. This increase is due mainly
- GlobeNewswire
Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2023 financial results after market close on Tuesday, November 28, 2023. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di
- GlobeNewswire
Kane Biotech Strengthens Board with Biotech Executive
Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of DirectorsWINNIPEG, Manitoba, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that John Coleman has been appointed to the Board of Directors of Kane Biotech effective immediately. Dr. Coleman brings a wealth of scientific and business expertise to the board. Currently serving as the President and CEO of
